Antitrust & Competition
High-growth means high-stakes—we help clients anticipate, track, and minimize exposure
With opportunity comes risk—especially in today’s innovation-driven global economy. As you continue to grow, your company faces increasing global scrutiny around antitrust and competition issues. Investigations into mergers, markets, cartels, and contractual arrangements between competitors, suppliers and distributors—as well as alleged abuse of dominant market positions—are on the rise. As antitrust authorities continue to expand the scope of their attention and explore new theories of harm, the risk of falling afoul of these complex laws has never been more acute.
From United States regulatory scrutiny and foreign investment issues to game-changing litigation in federal and state courts, our team is plugged into the specific issues and legal and economic challenges faced by today’s technology and life sciences companies. In fact, in the last year alone, our team has supported industry-leading companies such as AppLovin, Assa Abloy, Cisco Systems, Chinook Therapeutics, Databricks, Figma, Maze Therapeutics and Nextdoor Holdings in marquee M&A deals and investigative proceedings aimed at addressing competitive concerns, mitigating regulatory risks and securing necessary approvals for successful market integration.
Our lawyers have excellent working relationships with the Department of Justice (DOJ) Antitrust Division, the Federal Trade Commission (FTC) and numerous state attorneys general and have an intimate knowledge of what it takes to successfully navigate government investigations, and to help companies align their strategies with emerging antitrust realities. Our antitrust and competition lawyers work closely with our corporate, M&A, and litigation practices to help make sure our clients are covered.
We work together to address the most complex antitrust and competition challenges including:
- M&A and civil investigations practice before the FTC, DOJ, and state AG offices, dealing on a regular basis directly with the FTC and DOJ investigators responsible for technology and life science industries
- Successfully managing early-stage inquiries and advocacy to avoid prolonged and costly investigations and merger reviews
- Navigating the challenges of parallel reviews and investigations in jurisdictions across the globe
- Defending clients subject to conduct-related investigations in U.S. jurisdictions and abroad
- Counseling and advising clients on the issues and business practices critical to their industries, including R&D collaborations, patent pools and standard-setting, industry information exchanges, product interoperability, patent and copyright misuse, package licensing and bundling, marketing and distribution, and pricing and price discrimination
- Training and compliance programs, internal investigations, and audits, as well as document creation and retention policies and other antitrust best practices
- Leading the global defense (US DOJ Antitrust Division, EU, and CMA) of Figma’s proposed US$20 billion combination with Adobe.
- Representing Databricks in its $1.3 billion purchase of MosaicAI
- Representing AppLovin Corporation in its acquisition of Twitter, Inc.’s MoPub business for approximately $1 billion.
- Representing Nextdoor Holdings in connection with the US DOJ Antitrust Division’s Section 8 interlocking directorate investigation.
- Representing Vocera Communications in its acquisition by Stryker for a total equity value of approximately $2.97 billion and a total enterprise value of approximately $3.09 billion (including convertible notes).
- Leading the global defense (US DOJ Antitrust Division, EU, and CMA) of Figma’s proposed US$20 billion combination with Adobe.
- Representing Databricks in its $1.3 billion purchase of MosaicAI
- Representing AppLovin Corporation in its acquisition of Twitter, Inc.’s MoPub business for approximately $1 billion.
- Representing Nextdoor Holdings in connection with the US DOJ Antitrust Division’s Section 8 interlocking directorate investigation.
- Representing Vocera Communications in its acquisition by Stryker for a total equity value of approximately $2.97 billion and a total enterprise value of approximately $3.09 billion (including convertible notes).
- Representing Maze Therapeutics in the FTC investigation of its US$750 million exclusive worldwide license agreement with Sanofi for MZE00.
- Representing Sema4 in its $623 million acquisition of GeneDx, an OPKO Health subsidiary focused on genomic testing and analysis, and related $200 million PIPE financing.
- Representing Maze Therapeutics in the FTC investigation of its US$750 million exclusive worldwide license agreement with Sanofi for MZE00.
- Representing Sema4 in its $623 million acquisition of GeneDx, an OPKO Health subsidiary focused on genomic testing and analysis, and related $200 million PIPE financing.
- Representing Coca-Cola Bottlers’ Sales and Service in the FTC’s Robinson-Patman Act investigation of Coca-Cola and PepsiCo’s sales practices.
- Representing Clif Bar in its acquisition by Mondelēz International for $2.9 billion with additional significant contingent earnout consideration.
- Representing Coca-Cola Bottlers’ Sales and Service in the FTC’s Robinson-Patman Act investigation of Coca-Cola and PepsiCo’s sales practices.
- Representing Clif Bar in its acquisition by Mondelēz International for $2.9 billion with additional significant contingent earnout consideration.
